Source: Eur Respir J 2001; 17: 337-342
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Schols A.M.W.J., Wesseling G., Kester A.D.M., de Vries G., Mostert R., Slangen J., Wouters E.F.M.. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001; 17: 337-342

Member's Comments

No comment yet.

Related content which might interest you: Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD Source: Eur Respir J 2009; 33: 282-288 Year: 2009 Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Source: Eur Respir J 2003; 21: 260-266 Year: 2003 Statin use is associated with reduced mortality in COPD Source: Eur Respir J 2007; 29: 279-283 Year: 2007 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD Source: Eur Respir J 2010; 35: 1003-1021 Year: 2010 The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001 Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 A comparison of the effects of lung function between low dose theophylline and oral β2-agonist in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006 The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005 N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 795-798 Year: 2003 Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007 Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006 Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 R667 retinoid agonist modulates blood glucose in COPDe patients with improved metabolic profile compared to ATRA Source: Annual Congress 2007 - New drugs for COPD Year: 2007 Modern treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 60S-66S Year: 2001 Inhaled corticosteroids and hospitalisation due to exacerbation of COPD Source: Eur Respir J 2003; 22: 286-289 Year: 2003